Last Price$84.2(5.1%)
Market Cap$13.9B
LTM Research & Development Expenses (R&D)
$1,172.0M
YoY Growth
-12.7%
3Y CAGR
-0.4%
5Y CAGR
+12.6%
Stock quality & Intrinsic value
6/10
74.8% undervalued
Illumina, Inc. Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Jan'06 | Dec'06 | Dec'07 | Dec'08 | Jan'10 | Jan'11 | Jan'12 | Dec'12 | Dec'13 | Dec'14 | Jan'16 | Jan'17 | Dec'17 | Dec'18 | Dec'19 | Jan'21 | Jan'22 | Jan'23 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $27.7M | $33.4M | $73.9M | $100.0M | $140.6M | $177.9M | $196.9M | $231.0M | $276.7M | $388.1M | $401.5M | $504.4M | $546.0M | $623.0M | $647.0M | $682.0M | $1,185.0M | $1,321.0M | $1,354.0M | $1,169.0M |
Overvalued or undervalued?
Check the intrinsic value for ILMN
and see if it's the right time to invest.
Illumina, Inc. (ILMN) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Illumina, Inc.ILMN
$1,172.0M
(12.7%)
(0.4%)
12.6%
Median Peer Set
$204.6M
3.1%
0.3%
5.0%
Danaher CorporationDHR
$1,584.0M
5.4%
(3.1%)
4.9%
Thermo Fisher Scientific Inc.TMO
$1,390.0M
4.0%
(0.4%)
6.7%
Agilent Technologies, Inc.A
$464.0M
(2.9%)
0.7%
2.7%
Natera, Inc.NTRA
$357.6M
9.8%
16.7%
48.7%
IDEXX Laboratories, Inc.IDXX
$219.8M
15.1%
10.9%
10.5%
Mettler-Toledo International Inc.MTD
$189.4M
2.2%
3.7%
5.6%
Waters CorporationWAT
$183.0M
4.6%
2.8%
5.1%
Quest Diagnostics IncorporatedDGX
$0.0
N/A
N/A
N/A
IQVIA Holdings Inc.IQV
$0.0
N/A
N/A
N/A
Laboratory Corporation of America HoldingsLH
$0.0
(100.0%)
N/A
N/A
ILMN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Jan'06 | Dec'06 | Dec'07 | Dec'08 | Jan'10 | Jan'11 | Jan'12 | Dec'12 | Dec'13 | Dec'14 | Jan'16 | Jan'17 | Dec'17 | Dec'18 | Dec'19 | Jan'21 | Jan'22 | Jan'23 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 73.5 45.3% | 184.6 151.1% | 366.8 98.7% | 573.2 56.3% | 666.3 16.2% | 902.7 35.5% | 1,055.5 16.9% | 1,148.5 8.8% | 1,421.2 23.7% | 1,861.4 31.0% | 2,219.8 19.3% | 2,398.4 8.0% | 2,752.0 14.7% | 3,333.0 21.1% | 3,543.0 6.3% | 3,239.0 (8.6%) | 4,526.0 39.7% | 4,584.0 1.3% | 4,504.0 (1.7%) | 4,372.0 (2.9%) |
| Cost of Goods Sold (COGS) | 23.2 | 59.3 | 132.4 | 205.6 | 205.8 | 301.2 | 346.4 | 375.0 | 509.3 | 563.6 | 670.5 | 731.9 | 926.0 | 1,033.0 | 1,076.0 | 1,036.0 | 1,372.0 | 1,612.0 | 1,760.0 | 1,511.0 |
% margin | 50.3 68.5% | 125.2 67.9% | 234.4 63.9% | 367.6 64.1% | 460.6 69.1% | 601.5 66.6% | 709.1 67.2% | 773.5 67.4% | 911.9 64.2% | 1,297.7 69.7% | 1,549.3 69.8% | 1,666.4 69.5% | 1,826.0 66.4% | 2,300.0 69.0% | 2,467.0 69.6% | 2,203.0 68.0% | 3,154.0 69.7% | 2,972.0 64.8% | 2,744.0 60.9% | 2,861.0 65.4% |
| Operating Expenses | 56.0 | 87.4 | 232.2 | 262.5 | 323.6 | 389.9 | 500.6 | 517.0 | 657.8 | 854.3 | 926.2 | 1,087.4 | 1,220.0 | 1,417.0 | 1,482.0 | 1,623.0 | 3,277.0 | 2,618.0 | 4,010.0 | 3,694.0 |
| Research & Development Expenses (R&D) | 27.7 | 33.4 | 73.9 | 100.0 | 140.6 | 177.9 | 196.9 | 231.0 | 276.7 | 388.1 | 401.5 | 504.4 | 546.0 | 623.0 | 647.0 | 682.0 | 1,185.0 | 1,321.0 | 1,354.0 | 1,169.0 |
| Selling, General & Administrative Expenses (SG&A) | 28.0 | 54.1 | 101.3 | 148.0 | 176.3 | 221.0 | 303.7 | 286.0 | 381.0 | 466.3 | 524.7 | 583.0 | 674.0 | 794.0 | 835.0 | 941.0 | 2,092.0 | 1,297.0 | 1,612.0 | 1,092.0 |
% margin | (21.4) (29.2%) | 37.8 20.5% | (301.2) (82.1%) | 80.5 14.0% | 125.6 18.8% | 211.7 23.4% | 199.5 18.9% | 200.8 17.5% | 134.1 9.4% | 514.7 27.7% | 612.8 27.6% | 587.0 24.5% | 606.0 22.0% | 883.0 26.5% | 985.0 27.8% | 580.0 17.9% | (123.0) (2.7%) | (4,179.0) (91.2%) | (1,069.0) (23.7%) | (833.0) (19.1%) |
| Interest Income | 1.4 | 0.0 | 16.0 | 12.5 | 11.0 | 8.4 | 7.1 | 16.2 | 4.9 | 3.9 | 5.0 | 9.8 | 19.0 | 44.0 | 75.0 | 41.0 | 61.0 | 11.0 | 58.0 | 46.0 |
| Interest Expense | 15.8 | 0.0 | 648.9 | 42.9 | 23.7 | 24.6 | 34.8 | 37.8 | 39.7 | 41.7 | 42.1 | 33.2 | 37.0 | 57.0 | 52.0 | 49.0 | 61.0 | 26.0 | 77.0 | 100.0 |
| Pre-tax Income | (5.6) | 42.6 | (288.8) | 90.9 | 114.1 | 185.4 | 133.0 | 222.6 | 159.3 | 448.8 | 583.1 | 561.2 | 1,043.0 | 894.0 | 1,118.0 | 856.0 | 884.0 | (4,336.0) | (1,117.0) | (1,179.0) |
% effective tax rate | 31.0 (549.4%) | 2.7 6.2% | (10.4) 3.6% | 40.4 44.5% | 41.8 36.7% | 60.5 32.6% | 46.4 34.9% | 71.4 32.1% | 34.0 21.3% | 95.4 21.3% | 125.8 21.6% | 133.1 23.7% | 365.0 35.0% | 112.0 12.5% | 128.0 11.4% | 200.0 23.4% | 122.0 13.8% | 68.0 (1.6%) | 44.0 (3.9%) | 44.0 (3.7%) |
% margin | (20.9) (28.4%) | 40.0 21.7% | (278.4) (75.9%) | 50.5 8.8% | 72.3 10.8% | 124.9 13.8% | 86.6 8.2% | 151.3 13.2% | 125.3 8.8% | 353.4 19.0% | 461.6 20.8% | 462.6 19.3% | 726.0 26.4% | 826.0 24.8% | 1,002.0 28.3% | 656.0 20.3% | 762.0 16.8% | (4,404.0) (96.1%) | (1,161.0) (25.8%) | (1,223.0) (28.0%) |
| EPS | (0.26) | 0.45 | (2.57) | 0.43 | 0.59 | 1.01 | 0.70 | 1.23 | 1.00 | 2.61 | 3.18 | 3.15 | 4.97 | 5.62 | 6.82 | 4.46 | 5.08 | (28.05) | (7.35) | (7.69) |
| Diluted EPS | (0.26) | 0.41 | (2.57) | 0.38 | 0.53 | 0.87 | 0.62 | 1.13 | 0.90 | 2.37 | 3.10 | 3.13 | 4.91 | 5.54 | 6.72 | 4.43 | 5.05 | (28.05) | (7.35) | (7.69) |
% margin | (5.5) (7.5%) | 37.8 20.5% | 18.0 4.9% | 122.6 21.4% | 169.0 25.4% | 252.0 27.9% | 236.1 22.4% | 324.2 28.2% | 363.6 25.6% | 604.7 32.5% | 751.7 33.9% | 735.3 30.7% | 780.0 28.3% | 1,062.0 31.9% | 1,173.0 33.1% | 767.0 23.7% | 747.0 16.5% | (3,916.0) (85.4%) | (608.0) (13.5%) | (725.0) (16.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Illumina, Inc.'s Research & Development Expenses (R&D)?
As of today, Illumina, Inc.'s last 12-month Research & Development Expenses (R&D) is $1,172.0M, based on the financial report for Dec 29, 2024 (Q4’2024).
2) What is Illumina, Inc.'s Research & Development Expenses (R&D) growth rate?
Over the last year, Illumina, Inc.'s Research & Development Expenses (R&D) growth was (12.7%). The average annual Research & Development Expenses (R&D) growth rates for Illumina, Inc. have been 15.0% over the past three years, 12.6% over the past five years.
3) Is Illumina, Inc.'s Research & Development Expenses (R&D) growth rate Good?
Over the last year, Illumina, Inc.'s Research & Development Expenses (R&D) growth was (12.7%), which is lower than industry growth of (0.3%). It indicates that Illumina, Inc.'s Research & Development Expenses (R&D) growth is Good.